PreveCeutical Announces Further Positive Results from its Dual Gene Therapy Research Program
June 17, 2019, Vancouver, British Columbia: PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), is pleased to provide positive results from research conducted for its dual gene therapy research program (the “Program”).
PreveCeutical previously identified four or more novel siRNA constructs, each of which preferentially targeted the gene of interest while reducing the gene’s expression by no less than 80% compared to a random siRNA (control) sequence (see news release dated January 14, 2019).
The siRNA constructs represent the “therapeutic” component of the proposed gene therapy and are an important part of the gene therapy approach for potential application in type 2 diabetes and obesity. PreveCeutical’s research team has now identified and finalised a panel of highly potent and novel siRNA-candidates, each of which significantly (≥50%) silence the target gene and protein in mice and human-derived cells of interest. The lead siRNA sequences comprise those directed to the human variant of PTP-1B, and distinct sequences directed towards the mouse variant of PTP-1B. Synthetic efforts will now focus on introducing proprietary chemistries that enhance the biostability and thermostability of the novel siRNA sequences to generate modified siRNA sequences (“Smart-siRNAs”). Once the first series of Smart-siRNA’s are successfully developed, they are expected to be re-screened in cell-based assays to re-affirm their potency. This is anticipated to pave the way for evaluation in planned rodent models of disease, which would constitute the final phase of the Program.
PreveCeutical’s President and Chief Science Officer, Dr. Mak Jawadekar stated,
We are pleased with the progress being made given that these novel, potent siRNA constructs constitute the most crucial part of the gene therapy approach. This is a positive step in the right direction for the pursuit of our goal to achieve a successful dual gene therapy program
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilising organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
On Behalf of the Board of Directors
“Dr. Makarand (Mak) Jawadekar”
President& Chief Science Officer
For further information, please contact:
Director of Corporate Communications & Investor Relations
This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, matters related to the Company’s current and planned research and development programs, including the Program, the efficacy of the series of lead siRNA constructs and the potency of the Smart-siRNAs, the Company’s anticipated business plans and its prospect of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as “plans”, “expects”, “may”, “intends”, “anticipates”, “believes”, “proposes” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward looking statements are based on certain assumptions regarding the Company, including expected growth, results of operations, performance, industry trends and growth opportunities. Actual results could also differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to the inability of the Company, to, among other things, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities, commercialise therapeutic and diagnostic technologies, execute its proposed business plans, complete its research and product development programs as planned, including the Program, and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industries may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, intentions and assumptions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations intentions or assumptions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company’s filings are available at www.sedar.com